19 not yet recruiting. 19 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Not yet recruiting 19 |
| Phase 2 | 3 | Not yet recruiting 3 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Controls will receive two infusions of vehicle solution. - Acute Respiratory Distress Syndrome | Phase 3 | Not yet recruiting | Breathe Biologics, Inc. | 128 | 2027-03-01 | 2026-10-01 |
| Prediction and Prevention of Bloodstream Infections After Kidney Transplantation Pivmecillinam, Placebo - Kidney Transplant Infection, Bloodstream Infection | Phase 3 | Not yet recruiting | Susanne Dam Nielsen, MD, DMSc | 180 | 2027-01-01 | 2026-10-16 |
| Naproxen Versus Placebo as Adjunct Treatment of Cellulitis enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious | Phase 3 | Not yet recruiting | Ottawa Hospital Research Institute | 884 | 2026-11-01 | 2026-10-20 |
| Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With Sepsis Standard medical treatment, Ursodeoxycholic Acid - Sepsis | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 80 | 2026-10-01 | 2026-10-07 |
| STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis Hydrocortisone administration, Expanded antimicrobial therapy - Sepsis, Tuberculosis | Phase 3 | Not yet recruiting | University of Virginia | 344 | 2026-10-01 | 2026-06-01 |
| Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock Dexmedetomidine 100 µg/mL, intravenous solution, Stardard care - Septic Shock, Vasopressor Resistance | Phase 3 | Not yet recruiting | Hospices Civils de Lyon | 360 | 2026-09-01 | 2026-05-06 |
| Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients Melatonin - Therapy, Treatment | Phase 2 / Phase 3 | Not yet recruiting | Ain Shams University | 64 | 2026-07-21 | 2026-07-23 |
| Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction Dapaglifozin, Placebo - Septic Shock | Phase 3 | Not yet recruiting | University Hospital, Strasbourg, France | 568 | 2026-07-01 | 2026-03-27 |
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT Phosphate-containing Replacement Fluid, Standard Phosphate-free Replacement Fluid - Acute Kidney Injury, Sepsis | Phase 3 | Not yet recruiting | Sun Yat-sen University | 220 | 2026-05-01 | 2026-04-24 |
| Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis Etoposide (Early strategy), Etoposide (Delayed strategy) - Hemophagocytic Lymphohistiocytosis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 176 | 2026-04-01 | 2026-04-23 |
| ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS Anakinra, KINERET® - PEDIATRIC ACUTE MYOCARDITIS | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 110 | 2026-02-01 | 2026-01-28 |
| Effect of N-acetylcysteine as Adjunct Therapy on the Clinical Outcome of Neonatal Sepsis N-Acetyl Cysteine (NAC), Normal Saline - Neonatal Sepsis | Phase 3 | Not yet recruiting | Ain Shams University | 50 | 2026-02-01 | 2026-02-02 |
| Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) Human Albumin 20% Solution, Standard Care (in control arm) - Critical Illness, Septic Shock | Phase 3 | Not yet recruiting | Mahidol University | 304 | 2025-12-01 | 2025-11-19 |
| A Randomized Study of a Short Duration Therapy for Candidemia Standard of Care (SOC), Shortened duration of antifungal therapy - CANDIDEMIA | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 362 | 2025-07-01 | 2025-03-05 |
| Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial Levetiracetam IV, Placebo control - Septic Shock | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 280 | 2025-03-15 | 2025-03-12 |
| Venous Excess Ultrasound for Personalized Resuscitation in Septic Shock Venous Excess Ultrasound (VEXUS)-Guided Management - Septic Shock, Sepsis | Phase 3 | Not yet recruiting | Western University, Canada | 80 | 2024-12-01 | 2024-11-20 |
| Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock Methylene Blue, Placebo - Neonatal Sepsis, Shock, Septic | Phase 2 / Phase 3 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 130 | 2024-03-15 | 2024-03-12 |
Sepsis (6) · Shock, Septic (6) · Infections (2) · Neonatal Sepsis (2) · Acute Kidney Injury (1) · Anemia (1) · Bacteriuria (1) · Candidemia (1) · Cellulitis (1) · Communicable Diseases (1) · Critical Illness (1) · Cytokine Release Syndrome (1) · Fatigue (1) · Hyperemia (1)
Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Systemic Inflammatory Response Syndrome (13) · Infections (12) · Sepsis (6) · Shock (6) · Cardiovascular Diseases (4) · Vascular Diseases (3) · Bacterial Infections and Mycoses (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Connective Tissue Diseases (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
Saline Solution (2) · Standard of Care (2) · Acetylcysteine (1) · Amdinocillin Pivoxil (1) · Cephalexin (1) · Colchicine (1) · Dexmedetomidine (1) · Etoposide (1) · Interleukin 1 Receptor Antagonist Protein (1) · Melatonin (1) · Methylene Blue (1) · Naproxen (1) · Serum Albumin, Human (1) · Solutions (1) · Tablets (1)
Assistance Publique - Hôpitaux de Paris (4) · Ain Shams University (2) · Azienda Sanitaria Locale ASL 6, Livorno (1) · Breathe Biologics, Inc. (1) · Hospices Civils de Lyon (1) · Indiana University (1) · Mahidol University (1) · Ottawa Hospital Research Institute (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Sun Yat-sen University (1) · Susanne Dam Nielsen, MD, DMSc (1) · Tanta University (1) · University Hospital, Strasbourg, France (1) · University of Virginia (1) · Western University, Canada (1)
France (4) · Canada (2) · China (1) · Denmark (1) · Egypt (1) · India (1) · Tanzania (1) · Thailand (1) · Uganda (1)
Christopher C Moore, MD (1) · Eren Oyungu, MBChB, MMED (1) · Krishan Yadav, MD, MSc (1) · Megan S McHenry, MD, MS (1) · Scott K Heysell, MD, MPH (1) · Sourabh Dutta, MD, PhD (1)
PMID 11588440, PMID 12500513, PMID 12519925, PMID 14523635, PMID 14759425, PMID 16134766, PMID 17698886, PMID 18477932, PMID 21039362, PMID 21246318, PMID 21382993, PMID 26683506, PMID 26985370, PMID 27113697, PMID 27673307, PMID 28219057, PMID 28616212, PMID 28723883, PMID 29151412, PMID 29508706, PMID 29936590, PMID 30231909, PMID 31515724, PMID 32270211, PMID 32320987, PMID 32351011, PMID 32453920, PMID 32520577, PMID 34719443, PMID 36237547, PMID 36705345, PMID 36915146, PMID 8648456, PMID 9250657
2025 (3), U01AI192033 (1)